This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Richter, J. Articles by Sauter, G. Search for Related Content PubMed PubMed Citation Articles by Richter, J. Articles by Sauter, G.

(American Journal of Pathology. 1998;153:1615-1621.)
© 1998 American Society for Investigative Pathology

Regular Articles

Patterns of Chromosomal Imbalances in Advanced Urinary Bladder Cancer Detected by Comparative Genomic Hybridization

Jan Richter* , Lorenza Beffa* , Urs Wagner* , Peter Schraml* , Thomas C. Gasser , Holger Moch* , Michael J. Mihatsch* and Guido Sauter*

From the Institute of Pathology* and Urologic Clinics, University of Basel, Basel, Switzerland

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
To identify genetic changes linked to bladder cancer progression we analyzed 90 invasive transitional cell carcinomas (37 pT1 and 53 pT2–4) by comparative genomic hybridization. The most frequent alterations included 1q+ (37%), 5p+ (24%), 6q- (19%), 8p- (29%), 8q+ (37%), 9p- (31%), 9q- (23%), 11p- (24%), 11q- (22%), 17q+ (29%), and 20q+ (28%). Interestingly, there were three groups of alterations that frequently occurred together (9p- and 11q13+/20q+ and 11q13+ or 17q+/1q+ and 3p+ or 11q-). These loci might carry genes that interact with each other in specific molecular pathways. There were remarkable genetic similarities between minimally and deeply invasive tumors of different histological grades, including a similar number of aberrations per tumor and an equal frequency of most individual alterations. However, deletions of 5q, 6q, and 15q and gains of 5p, 7p, and Xq were significantly more frequent in pT2–4 than in pT1 carcinomas. These loci may harbor genes that are important for bladder cancer progression.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

It appears likely that progression from minimally invasive to deeply invasive cancer goes along with the acquisition of genomic alterations increasing the malignant potential of cancer cells. Previous studies investigating specific alterations have suggested that at least a few molecular changes are more frequent in pT2–4 than in pT1 carcinomas, including epidermal growth factor receptor (EGFR) overexpression and loss of heterozygosity (LOH) at 3p.^1,2 A systematic genome-wide screening for differences between the stages pT1 and pT2–4 has not been performed. Previous studies attempting a comprehensive analysis of the entire genome by either allelotype studies or comparative genomic hybridization (CGH) have focused on early-stage tumors^3,4 or analyzed only a small number of tumors.^5,6 In this study, we analyzed a series of 90 invasive urinary bladder carcinomas by CGH to search for genomic alterations that are associated with tumor progression. CGH allows detection of all relative DNA sequence copy number gains and losses of a tumor in one examination.⁷ The results implicate several genomic alterations that may play a role in bladder cancer progression.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Tumor Material

Formalin-fixed, paraffin-embedded primary bladder tumors were from the archives of the Institute of Pathology, University Hospital Basel, Basel, Switzerland. Thirty-seven papillary pT1, twenty-four papillary pT2–4, and twenty-nine solid pT2–4 carcinomas were randomly selected from a series that had been reviewed by a single pathologist (G. Sauter). The CGH findings of 27 of our pT1 carcinomas have previously been published.⁴ Tumor stage and grade were defined according to Union Internationale Contre le Cancer (UICC) and World Health Organization classifications.^8,9 Only tumors for which histological staging was unequivocal were included in this study. A papillary tumor growth was assumed if at least one unequivocal papilla with similar atypia as in the invasive tumor area was present. The histological tumor grade was grade 2 in 15 and grade 3 in 22 pT1 tumors and grade 2 in 14 and grade 3 in 39 pT2–4 carcinomas. Of the 53 muscle-invasive tumors, 24 had a papillary and 29 had a solid growth pattern. Sixty-six patients were male, and twenty-four were female. Tumor-specific survival data were available from 67 patients. Tumor-specific 5-year survival was markedly shorter in 30 patients with pT2–4 carcinomas (50%) than in 37 patients with pT1 carcinomas (89%, P < 0.0001).

DNA Preparation

All tumor blocks were trimmed to enrich for tumor. Twenty 10-µm-thick sections were taken for DNA extraction. The first and the last sections were stained with hematoxylin and eosin. Tumors having an average tumor cell content of less than 75% in these sections were excluded. DNA extraction and labeling was as described.⁴ One microgram of tumor DNA was nick translated by using a commercial kit (BioNick kit, Life Technologies, Gaithersburg, MD) and Spectrum Green-dUTPs (Vysis, Downers Grove, IL) for direct labeling of tumor DNA. Spectrum Red-labeled normal reference DNA (Vysis) was used for cohybridization.

CGH and Digital Image Analysis

The hybridization mixture consisted of 200 ng of Spectrum Green-labeled tumor DNA, 200 ng of Spectrum Red-labeled normal reference DNA, and 20 µg of Cot-1 DNA (GIBCO, Gaithersburg, MD) dissolved in 10 µl of hybridization buffer (50% formamide, 10% dextran sulfate, 2X SSC, pH 7.0). Hybridization was over 3 days at 37°C to normal metaphase spreads (Vysis). Posthybridization washes were as described.⁴ Digital images were collected from six to seven metaphases using a Photometrics cooled CCD camera (Microimager 1400, Xillix Technologies, Vancouver, British Columbia, Canada) and a Sun workstation. The VYSIS software program was used to calculate average green-to-red ratio profiles for each chromosome. At least four observations per autosome and two observations per sex chromosome were included in each analysis.

Controls and Threshold Definition

Each CGH experiment included a tumor cell line (Spectrum Green MPE-600, Vysis) with known aberrations (positive control) and a hybridization of two differentially labeled sex-mismatched normal DNAs to each other (negative control). Sex-mismatched normal controls were also used to test the ability of each metaphase batch to allow for a linear relationship between fluorescence intensities and DNA sequence copy numbers. Metaphases were used only if the color ratio of sex-mismatched normal DNAs was 0.66 at the X chromosome. Thresholds used for definition of DNA sequence copy number gains and losses were based on the results of CGH analyses of formalin-fixed normal tissues. A gain of DNA sequences was assumed at chromosomal regions where the hybridization resulted in a tumor-to-normal ratio of 1.20. Overrepresentations were considered amplifications when the fluorescence ratio values exceeded 1.5 in a subregion of a chromosome arm. A loss of DNA sequences was presumed at chromosomal regions where the tumor-to-normal ratio was 0.80. To define an aberration it was additionally required that the first SD was above (gain) or below (deletion) 1.00. As some false aberrations were detected in normal tissues at 1p, 16p, 19, and 22, these G-C-rich regions, known to produce false positive results by CGH, were excluded from all analyses.

Statistics

Contingency table analysis was used to analyze the relationship between genomic alterations, grade, stage, and growth pattern. A Student t-test was applied to compare the number of genomic alterations between tumors of different grades and stages. A log rank test was applied to examine the relationship between tumor stage and tumor-specific survival.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
CGH Findings

The total number of aberrations per tumor ranged from 0 to 24 (mean, 7.5). Deletions (3.8 ± 2.7) were slightly more frequent than gains of chromosomal material (3.4 ± 2.8). Eight tumors had no detectable aberrations. One pT1G2 carcinoma had a 9p deletion as a sole aberration. The CGH findings of all 90 tumors examined in this study are shown in Figure 1, A (37 papillary pT1 carcinomas), B (24 papillary pT2–4 carcinomas), C (29 solid pT2–4 carcinomas). Overall, deletions were most prevalent at 2q33-ter (17%), 4q25–31 (10%), 5q (18%, consensus regions 5q12–13 and 5q22–23), 6q21–24 (19%), 8p (29%), 9p (31%), 9q21–33 (23%), 10q25–26 (17%), 11p14–15 (24%), 11q23–25 (22%), 13q (11%, 13q21 and 13q31–34), 17p (19%), 18q21-ter (12%), Xp (11%), Xq24-ter (8%), and Y (22%). A gain of chromosomal material was most commonly seen at 1q (37%, consensus regions 1q22–24 and 1q32-ter), 3p23–24 (13%), 5p14–15 (24%), 6p21–22 (16%), 7p15–22 (20%), 8q (37%, 8q21.3–22 and 8q24), 10p13–15 (19%), 12q (14%, 12q15–21.2 and 12q24), 17q (29%, 17q21 and 17q25), 20p (9%), and 20q13 (28%).

View larger version (48K): [in this window] [in a new window]   Figure 1. Summary of all relative DNA sequence copy number changes detected by CGH in 37 papillary pT1 (A), 24 papillary pT2–4 (B), and 29 solid pT2–4 carcinomas (C). The vertical lines on the right side of the chromosome idiograms indicate gains, those on the left losses of the corresponding chromosomal regions. Amplifications are indicated as solid bars. *1p, 16p, 19, and 22 were not analyzed.

Interestingly, there were strong associations between some individual alterations. For example, gains of 11q13 were associated with 9p deletions. 9p deletions were seen in 6 of 8 tumors (75%) with an 11q13 gain but in only 22 of 82 tumors without 11q gain (27%, P = 0.005). Gains of 20q were linked to gains of both 17q and 11q13 (Figure 2) . An 11q13 gain was observed in 6 of 25 tumors (24%) with a 20q gain but in only 2 of 65 tumors without a 20q gain (3%, P = 0.0018). 17q gains were present in 13 of 25 tumors (52%) with a 20q gain but in only 12 of 65 tumors without 20q gain (18%, P = 0.0015). An additional gain of 11q13 or 17q was present in 68% of all tumors with a 20q gain, as 11q13 gains and 17q gains coincided rarely (only two tumors had both alterations). Similarly, 1q gains were associated with 3p gains and 11q deletions (Figure 2) . An 11q deletion was present in 15 of 33 tumors (45%) with 1q gain as compared with only 5 of 57 tumors without 1q gain (9%, P = 0.0001). And 9 of 33 tumors (27%) with 1q gain had a 3p gain as compared with only 3 of 57 tumors without 1q gain (5%, P = 0.0031). There was no association between 3p gains and 11q deletions (P = 0.32). Sixty-one percent of all tumors with a 1q gain had an additional 11q deletion or a 3p gain.

View larger version (40K): [in this window] [in a new window]   Figure 2. Relationship between individual alterations. Tumors with 20q gains had an increased likelihood to have also 11q13 gains or 17q gains. Carcinomas with 1q gains had frequent 3p gains and 11q deletions.

There was no significant increase in the number of detectable aberrations with stage and grade of the tumors. pT1 tumors had 3.0 ± 2.3 deletions, 2.7 ± 2.8 gains, and 0.4 ± 0.8 amplifications per tumor resulting in a total of 6.1 ± 4.9 alterations. This was only insignificantly less than found in pT2–4 tumors (3.8 ± 2.9 deletions, 3.8 ± 2.7 gains, 0.4 ± 0.7 amplifications, and 7.9 ± 4.9 total aberrations). Grade 2 carcinomas had 3.0 ± 2.6 deletions, 2.6 ± 2.7 gains, 0.3 ± 0.8 amplifications, and 5.8 ± 5.0 alterations in total. These numbers were somewhat higher in grade 3 carcinomas (3.7 ± 2.7 deletions, 3.7 ± 2.7 gains, 0.4 ± 0.7 amplifications, and 7.8 ± 4.8 total aberrations), but the difference between grade 2 and grade 3 did not achieve significance. To screen for specific alterations that might be linked to tumor progression, we compared the CGH findings of 37 papillary pT1 and 24 papillary pT2–4 carcinomas (Table 1) . This analysis showed that deletions of 5q, 6q, and 15q as well as gains of 5p, 7p, and Xq were significantly linked to high stage. These aberrations were also common in solid pT2–4 carcinomas. The relationship between tumor grade and specific alterations was clearly less prominent. Only gains of 6p were significantly more frequent in grade 3 than in grade 2 tumors (P = 0.02). 9q deletions and 11q13 gains were the only alterations showing significant differences in frequency between papillary and solid muscle-invasive carcinomas (Table 1) . Deletions of 5q (P < 0.0038) and 10p gains (P < 0.0353) were linked to poor outcome within these 67 patients with tumor-specific survival data. 1q+, 5p+, 6q-, 7p+, 8p-, 8q+, 9p-, 9q-, 11p-, 11q-, 15q-, 17q+, 20q+, and Xq were not significantly associated with the tumor-specific survival of our patients.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

The statistical analyses for comparison of the CGH findings in carcinomas having limited (pT1) and extensive (pT2–4) invasion was restricted to papillary carcinomas because previous studies had suggested genetic differences between solid and papillary tumors.¹⁴ Several alterations were significantly more frequent in pT2–4 than in pT1 carcinomas, including deletions of 5q, 6q, and 15q as well as gains of 5p, 7p, and Xq. Most of these changes have only rarely been reported in bladder carcinomas, probably because previous studies have either examined specific loci not including these regions or focused on early-stage tumors.^3-5 It is tempting to speculate that these loci might carry genes of which a malfunction can contribute to bladder cancer progression. It cannot be excluded that one or several of these loci carry genes with relevance for invasive tumor growth, as alterations that are necessary for invasion may be present only in subpopulations of pT1 carcinomas, not detectable by CGH, but in a much higher fraction of the tumor cells if a cancer is predominantly growing invasively (stage pT2–4). Deletions of 5q and gains of 10p were significantly related to poor outcome in our patients. However, these alterations were strongly associated with advanced stage, and prognosis was markedly different between pT1 and pT2–4 tumors. Additional studies on larger sets of patients are required to evaluate whether cytogenetic changes are linked to the risk of progression in pT1 and to tumor-specific survival and metastasis in pT2–4 carcinomas.

To screen for genetic differences between tumors with different growth patterns, we compared the CGH results of 24 papillary and 29 solid muscle-invasive carcinomas. Deletions of 9q and gains of 11q13 were the only two alterations showing significant differences between papillary and solid tumors. The higher frequency of 9q deletions in papillary than in solid carcinomas is in line with previous studies suggesting that chromosome 9 deletions may be characteristic for papillary tumors.^14,15 As 9p deletions were not significantly linked to papillary growth pattern, our data would be consistent with the location of a gene linked to papillary tumor growth on 9q rather than on 9p. This is in agreement with the findings of Simoneau et al¹⁶ showing that 9q deletions were more frequent than 9p deletions in papillary pTa tumors. Interestingly, gains of 11q13 were also associated with a papillary growth pattern. A role for cyclin D1 (located at 11q13) overexpression has recently been described in low-grade and low-stage bladder tumors.^17,18 In a previous study we analyzed 393 bladder neoplasms for cyclin D1 expression and found that papillary tumor growth but not low grade or low stage was independently linked to cyclin D1 expression.¹⁹

The high number of tumors examined in this study enabled us to search for alterations that frequently occur together. Loci that are frequently affected together might carry genes that interact in specific molecular pathways. The significant association between 11q13 gains and 9p deletions is an example of a combination of alterations that might involve genes with known interaction. Although expression analyses have not been performed in this study, it is tempting to speculate that 11q13 amplification, most likely leading to cyclin D1 overexpression,¹⁷ may give tumor cells a particularly significant growth advantage if the cyclin D1 inhibitors p16/p15 on 9p are also affected. Even more striking associations could be found for two other groups of alterations: 20q gains were strongly linked to both gains of 17q and 11q13, and 1q gains were associated with both 3p gains and 11q deletions. Although there are currently no clues on the potentially involved genes, it appears possible that genes at these loci could interact with each other. It could be speculated that, for example, overexpression of a gene on 1q will exert a particularly strong oncogenic role if either a tumor suppressor gene on 11q is inactivated or another gene on 3p is co-overexpressed.

It is assumed that circumscribed high-level amplifications are linked to the overexpression of oncogenes. Previous studies using Southern blotting, fluorescence in situ hybridization, conventional cytogenetics, or CGH have described 21 regions of the genome that can be amplified in urinary bladder cancer including the sites of the known oncogenes erbB-2, EGFR, cyclin D1, and c-myc as well as 1q21–31, 2q13, 3p22–24, 6p22, 8p11, 8q21, 9p21, 10p13–14, 12q13–15, 13q13, 13q31–33, 18p11, 20q, 21p11, 22q11–13, Xp11–13, and Xq21–22.2.^4-6,20-24 In this study, 30 high-level amplifications were found at 14 different loci, including 13 regions where amplifications had previously been described in bladder cancer. The only amplification site that was newly detected in this study was located at 5p14–15. Although gains involving the entire 5p occur frequently in bladder cancer, this finding is consistent with a target gene in the 5p14–15 region. The shortage of new amplification sites found in this set of advanced tumors suggests that the list of genomic regions that can be amplified in urothelial neoplasms is more or less complete. Additional investigations will now have to identify overexpressed target genes at these sites.

Taken together, the results of this and other studies suggest that several groups of chromosomal alterations may be associated with specific steps along bladder cancer progression (Figure 3) . Deletions of 9p, 1q gains, and Y losses are frequent in bladder tumors of all grades and stages and may therefore occur early in bladder cancer development.^4,25,26 The significantly higher frequency of 9q deletions and 11q13 (cyclin D1) gains in papillary than in solid tumors is consistent with a role of genes at these loci for papillary tumor growth. Cytogenetic alterations such as 2q-, 8p-, 8q+, 9p-, 11p-, 11q-, 17q+, and 20q+ can be found at a comparable frequency in papillary and solid invasive carcinomas irrespective of the invasion level. Several of these alterations are also frequent in carcinoma in situ,^27,28 suggesting a considerable similarity between noninvasive and invasive high-grade neoplasias on the level of gross genomic alterations. These cytogenetic changes as well as 17p deletions, which are difficult to detect by CGH because of the small size of 17p, and p53 mutations may be characteristic for a genetically unstable bladder neoplasm that is distinct from low-grade pTa tumors. Cytogenetic changes that are more frequent in pT2–4 than in pT1 carcinomas, such as 5p+, 5q-, 6q-, 7p+, 15q-, and Xq+, may carry genes that play a role for tumor progression. Additional studies are now required to evaluate which are the target genes of cytogenetic lesions and to translate our knowledge on the genetic background of bladder cancer into clinical applications.

View larger version (28K): [in this window] [in a new window]   Figure 3. A putative model of bladder cancer development and progression based on molecular cytogenetic findings. For explanations, see text.

	Acknowledgements

 
We thank Ms. Carole Egenter, Ms. Hedvika Novotny, Ms. Martina Storz, Ms. Martina Mirlacher, and the staff of the Institute of Pathology, University of Basel, for their excellent technical support. We thank Prof. Robert McGandy for helpful discussions and proofreading the manuscript.

	Footnotes

 
Address reprint requests to Dr. Guido Sauter, Institute of Pathology, University Hospital, Schönbeinstrasse 40, 4003 Basel, Switzerland. E-mail: sauter{at}ubaclu.unibas.ch

Supported by Schweizerische Krebsliga (SKL 137-7-1995), Krebsliga Beider Basel, Schweizerischer Nationalfonds (NF 3200–043969.95.1), and Stiftung für Klinische Krebsforschung der Onkologischen Abteilung des Kantonsspitals Basel.

Accepted for publication August 3, 1998.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Neal D, Marsh C, Bennet M, Abel P, Hall R, Sainsbury J, Harris A: Epidermal-growth-factor receptor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985, 1:366-368[Medline]
2. Li M, Zhang ZF, Reuter VE, Cordon Cardo C: Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol 1996, 149:229-235[Abstract]
3. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG: Allelotype of human bladder cancer. Cancer Res 1994, 54:531-538[Abstract/Free Full Text]
4. Richter J, Jiang F, Görög J, Sartorius G, Moch H, Egenter C, Gasser T, Mihatsch M, Sauter G: Marked genetic differences between pTa and pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997, 57:2860-2864[Abstract/Free Full Text]
5. Voorter C, Joos S, Bringuier PP, Vallinga M, Poddighe P, Schalken J, du Manoir S, Ramaekers F, Lichter P, Hopman A, Voorter C, Joos S, Bringuier PP, Vallinga M, Poddighe P, Schalken J, du Manoir S, Ramaekers F, Lichter P, Hopman A: Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am J Pathol 1995, 146:1341-1354[Abstract]
6. Kallioniemi A, Kallioniemi O, Citro G, Sauter G, DeVries S, Kerschmann R, Carroll P, Waldman F: Identification of novel DNA amplifications and deletions in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes & Cancer 1995, 12:213-219[Medline]
7. Kallioniemi A, Kallioniemi O, Sudar D, Rutovitz D, Gray J, Waldman F, Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992, 258:818-821[Abstract/Free Full Text]
8. UICC: TNM Classification of Malignant Tumours. Berlin, Springer, 1992
9. Mostofi F: Histological Typing of Urinary Bladder Tumors. 1973 World Health Organization, Geneva
10. Knowles MA, Shaw ME, Proctor AJ: Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 1993, 8:1357-1364[Medline]
11. Presti J, Reuter V, Galan T, Fair W, Cordon-Cardo C: Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 1991, 51:5405-5409[Abstract/Free Full Text]
12. Powell I, Tyrkus M, Kleer E: Apparent correlation of sex chromosome loss and disease course in urothelial cancer. Cancer Genet Cytogenet 1990, 50:97-101[Medline]
13. Shipman R, Schraml P, Colombi M, Raefle G, Ludwig CU: Loss of heterozygosity on chromosome 11p13 in primary bladder carcinoma. Hum Genet 1993, 91:455-458[Medline]
14. Spruck CHI, Ohneseit PF, Gonzalez ZM, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG, Jones PA: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 54:784-788[Abstract/Free Full Text]
15. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon CC: Genetic alterations in bladder cancer. Lancet 1993, 342:469-471[Medline]
16. Simoneau A, Spruck C, Gonzalez Z, M, Gonzalgo M, Chan M, Tsai Y, Dean M, Steven K, Horn T, Jones P: Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res 1996, 56:5039-5043[Abstract/Free Full Text]
17. Bringuier PP, Tamimi Y, Schuuring E, Schalken J: Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene 1996, 12:1747-1753[Medline]
18. Lee C, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, Ikemoto S, Nakatani T, Wada S, Kishimoto T, Fukushima S: Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 1997, 79:780-789[Medline]
19. Wagner U, Süess K, Schmid U, Ackermann D, Zellweger T, Maurer R, Alund G, Knönagel H, Rist M, Jordan P, Moch H, Mihatsch MJ, Gasser T, Sauter G: Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1998 (in press)
20. Sauter G, Moch H, Carroll P, Kurschmann R, Mihatsch M, Waldman F: Chromosome 9 loss detected by fluorescence in situ hybridization. Int J Cancer 1995, 64:99-103[Medline]
21. Mitelman F: Catalog of Chromosome Aberrations in Cancer. 1994 Wiley-Liss, New York
22. Proctor AJ, Coombs LM, Cairns JP, Knowles MA: Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene 1991, 6:789-795[Medline]
23. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, Knowles MA: Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991, 63:601-608[Medline]
24. Sauter G, Carroll P, Moch H, Kallioniemi A, Kurschmann R, Narayam P, Mihatsch M, Waldman F: Increased c-myc gene copy number in advanced bladder cancer. Am J Pathol 1995, 146:1131-1139[Abstract]
25. Cairns P, Shaw ME, Knowles MA: Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993, 8:1083-1085[Medline]
26. Sauter G, Moch H, Wagner U, Novotna H, Gasser T, Mattarelli G, Mihatsch M, Waldman F: Y Chromosome loss detected by FISH in bladder cancer. Cancer Genet Cytogenet 1995, 82:163-169[Medline]
27. Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch M, Waldmn F: Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 1995, 26:970-978[Medline]
28. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D: Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995, 55:5213-5216[Abstract/Free Full Text]

This article has been cited by other articles:

				G. C Santos, M Zielenska, M Prasad, and J A Squire Chromosome 6p amplification and cancer progression J. Clin. Pathol., January 1, 2007; 60(1): 1 - 7. [Abstract] [Full Text] [PDF]

				M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]

				J. D. Raman, N. P. Mongan, S. K. Tickoo, S. A. Boorjian, D. S. Scherr, and L. J. Gudas Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder Clin. Cancer Res., December 15, 2005; 11(24): 8570 - 8576. [Abstract] [Full Text] [PDF]

				K. Koed, C. Wiuf, L.-L. Christensen, F. P. Wikman, K. Zieger, K. Moller, H. von der Maase, and T. F. Orntoft High-Density Single Nucleotide Polymorphism Array Defines Novel Stage and Location-Dependent Allelic Imbalances in Human Bladder Tumors Cancer Res., January 1, 2005; 65(1): 34 - 45. [Abstract] [Full Text] [PDF]

				M. Zheng, R. Simon, M. Mirlacher, R. Maurer, T. Gasser, T. Forster, P. A. Diener, M. J. Mihatsch, G. Sauter, and P. Schraml TRIO Amplification and Abundant mRNA Expression Is Associated with Invasive Tumor Growth and Rapid Tumor Cell Proliferation in Urinary Bladder Cancer Am. J. Pathol., July 1, 2004; 165(1): 63 - 69. [Abstract] [Full Text] [PDF]

				A. J. Evans, B. L. Gallie, M. A.S. Jewett, G. R. Pond, K. Vandezande, J. Underwood, Y. Fradet, G. Lim, P. Marrano, M. Zielenska, et al. Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain Reaction Am. J. Pathol., January 1, 2004; 164(1): 285 - 293. [Abstract] [Full Text] [PDF]

				J. A. Veltman, J. Fridlyand, S. Pejavar, A. B. Olshen, J. E. Korkola, S. DeVries, P. Carroll, W.-L. Kuo, D. Pinkel, D. Albertson, et al. Array-based Comparative Genomic Hybridization for Genome-Wide Screening of DNA Copy Number in Bladder Tumors Cancer Res., June 1, 2003; 63(11): 2872 - 2880. [Abstract] [Full Text] [PDF]

				M. O. Hoque, C.-C. R. Lee, P. Cairns, M. Schoenberg, and D. Sidransky Genome-Wide Genetic Characterization of Bladder Cancer: A Comparison of High-Density Single-Nucleotide Polymorphism Arrays and PCR-based Microsatellite Analysis Cancer Res., May 1, 2003; 63(9): 2216 - 2222. [Abstract] [Full Text] [PDF]

				L. E. Moore, A. H. Smith, C. Eng, D. Kalman, S. DeVries, V. Bhargava, K. Chew, D. Moore II, C. Ferreccio, O. A. Rey, et al. Arsenic-Related Chromosomal Alterations in Bladder Cancer J Natl Cancer Inst, November 20, 2002; 94(22): 1688 - 1696. [Abstract] [Full Text] [PDF]

				S. Sen, H. Zhou, R.-D. Zhang, D. S. Yoon, F. Vakar-Lopez, S. Ito, F. Jiang, D. Johnston, H. B. Grossman, A. C. Ruifrok, et al. Amplification/Overexpression of a Mitotic Kinase Gene in Human Bladder Cancer J Natl Cancer Inst, September 4, 2002; 94(17): 1320 - 1329. [Abstract] [Full Text] [PDF]

				G. Dominguez, J. Carballido, J. Silva, J. M. Silva, J. M. Garcia, J. Menendez, M. Provencio, P. Espana, and F. Bonilla p14ARF Promoter Hypermethylation in Plasma DNA as an Indicator of Disease Recurrence in Bladder Cancer Patients Clin. Cancer Res., April 1, 2002; 8(4): 980 - 985. [Abstract] [Full Text] [PDF]

				H. Primdahl, F. P. Wikman, H. von der Maase, X.-g. Zhou, H. Wolf, and T. F. Orntoft Allelic Imbalances in Human Bladder Cancer: Genome-Wide Detection With High-Density Single-Nucleotide Polymorphism Arrays J Natl Cancer Inst, February 6, 2002; 94(3): 216 - 223. [Abstract] [Full Text] [PDF]

				T. F. Orntoft, T. Thykjaer, F. M. Waldman, H. Wolf, and J. E. Celis Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-invasive and Invasive Human Transitional Cell Carcinomas Mol. Cell. Proteomics, January 1, 2002; 1(1): 37 - 45. [Abstract] [Full Text] [PDF]

				M. Hoglund, T. Sall, S. Heim, F. Mitelman, N. Mandahl, and I. Fadl-Elmula Identification of Cytogenetic Subgroups and Karyotypic Pathways in Transitional Cell Carcinoma Cancer Res., November 1, 2001; 61(22): 8241 - 8246. [Abstract] [Full Text] [PDF]

				M A Knowles What we could do now: molecular pathology of bladder cancer Mol. Pathol., August 1, 2001; 54(4): 215 - 221. [Abstract] [Full Text] [PDF]

				R. Simon, J. Richter, U. Wagner, A. Fijan, J. Bruderer, U. Schmid, D. Ackermann, R. Maurer, G. Alund, H. Knonagel, et al. High-Throughput Tissue Microarray Analysis of 3p25 (RAF1) and 8p12 (FGFR1) Copy Number Alterations in Urinary Bladder Cancer Cancer Res., June 1, 2001; 61(11): 4514 - 4519. [Abstract] [Full Text] [PDF]

				R. Simon, E. Eltze, K.-L. Schäfer, H. Bürger, A. Semjonow, L. Hertle, B. Dockhorn-Dworniczak, H.-J. Terpe, and W. Böcker Cytogenetic Analysis of Multifocal Bladder Cancer Supports a Monoclonal Origin and Intraepithelial Spread of Tumor Cells Cancer Res., January 1, 2001; 61(1): 355 - 362. [Abstract] [Full Text]

				M. Muscheck, H. Abol-Enein, K. Chew, D. Moore II, V. Bhargava, M.A. Ghoneim, P.R. Carroll, and F.M. Waldman Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization Carcinogenesis, September 1, 2000; 21(9): 1721 - 1726. [Abstract] [Full Text] [PDF]

				J. Richter, U. Wagner, J. Kononen, A. Fijan, J. Bruderer, U. Schmid, D. Ackermann, R. Maurer, G. Alund, H. Knonagel, et al. High-Throughput Tissue Microarray Analysis of Cyclin E Gene Amplification and Overexpression in Urinary Bladder Cancer Am. J. Pathol., September 1, 2000; 157(3): 787 - 794. [Abstract] [Full Text] [PDF]

				P. J. Grippo and E. P. Sandgren Highly Invasive Transitional Cell Carcinoma of the Bladder in a Simian Virus 40 T-Antigen Transgenic Mouse Model Am. J. Pathol., September 1, 2000; 157(3): 805 - 813. [Abstract] [Full Text] [PDF]

				J. Bruch, W. A. Schulz, J. Häussler, I. Melzner, S. Brüderlein, P. Möller, R. Kemmerling, W. Vogel, and H. Hameister Delineation of the 6p22 Amplification Unit in Urinary Bladder Carcinoma Cell Lines Cancer Res., August 1, 2000; 60(16): 4526 - 4530. [Abstract] [Full Text]

				J. W. Gray and C. Collins Genome changes and gene expression in human solid tumors Carcinogenesis, March 1, 2000; 21(3): 443 - 452. [Abstract] [Full Text] [PDF]

				J. Richter, U. Wagner, P. Schraml, R. Maurer, G. Alund, H. Knonagel, H. Moch, M. J. Mihatsch, T. C. Gasser, and G. Sauter Chromosomal Imbalances Are Associated with a High Risk of Progression in Early Invasive (pT1) Urinary Bladder Cancer Cancer Res., November 1, 1999; 59(22): 5687 - 5691. [Abstract] [Full Text] [PDF]

				V. Toma, D. Hauri, U. Schmid, D. Ackermann, R. Maurer, G. Alund, H. Knonagel, M. Rist, T. C. Gasser, G. Sauter, et al. Focal Loss of CD44 Variant Protein Expression is Related to Recurrence in Superficial Bladder Carcinoma Am. J. Pathol., November 1, 1999; 155(5): 1427 - 1432. [Abstract] [Full Text] [PDF]

				J. Zhao, J. Richter, U. Wagner, B. Roth, P. Schraml, T. Zellweger, D. Ackermann, U. Schmid, H. Moch, M. J. Mihatsch, et al. Chromosomal Imbalances in Noninvasive Papillary Bladder Neoplasms (pTa) Cancer Res., September 1, 1999; 59(18): 4658 - 4661. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Richter, J. Articles by Sauter, G. Search for Related Content PubMed PubMed Citation Articles by Richter, J. Articles by Sauter, G.